3 Innovation Stocks With Parabolic Upside Potential

Key Points

• aTyr Pharma's lead drug could transform treatment for pulmonary sarcoidosis, with phase 3 results due in Q3 2025 and analysts forecasting 400% upside.

• Zeta Global's AI marketing cloud is growing revenue at 35% annually, positioning it to capture a significant share of the trillion-dollar-plus digital marketing market.

• Vertical Aerospace's eVTOL aircraft could revolutionize urban transportation, with commercial flights targeted for 2028 and a $6 billion order book.

• 10 stocks we like better than Zeta Global ›

Innovation unlocks value -- but it doesn't come without risk. From breakthrough drugs and artificial intelligence (AI)-powered marketing to flying taxis, these three companies are attacking massive markets with transformative technology.

For investors willing to stomach volatility, the upside could be exponential.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Image source: Getty Images.

Rewriting the immunology playbook

aTyr Pharma (NASDAQ: LIFE) doesn't just develop drugs. The company is rewriting the rules of immunology. aTyr has discovered that transfer RNA synthetases -- proteins everyone thought just helped build other proteins -- actually moonlight as powerful immune system modulators.

aTyr's lead drug, efzofitimod, just completed enrollment in its phase 3 EFZO-FIT trial for pulmonary sarcoidosis, with results expected in 2025's third quarter. Since EFZO-FIT is a single phase 3 trial, regulatory approval may require either an exceptionally strong data package or a confirmatory study, making the readout all the more pivotal.

This isn't a small market opportunity. Over 200,000 Americans suffer from sarcoidosis, and current treatments are limited to steroids with brutal side effects. In phase 1b/2a, the highest dose of efzofitimod achieved a 58% reduction in steroid use from baseline, with 33% of patients able to taper off steroids completely. If phase 3 confirms these results, aTyr could capture a market worth $2 billion annually.

What makes aTyr particularly compelling at today's $5.25 share price (as of Aug. 7, 2025) is the disconnect between its market cap and potential. Analysts have an average price target of $25, implying 376% upside. With $78.8 million in cash and a burn rate of about $15 million per quarter, aTyr has runway through the pivotal phase 3 readout. Risk remains high, as any clinical-stage biotech faces binary outcomes. But for investors willing to bet on innovation, aTyr offers asymmetric upside.

Digital marketing's AI revolution

While aTyr reimagines biology, Zeta Global (NYSE: ZETA) is revolutionizing how companies connect with customers. Zeta's AI Marketing Cloud processes over 1 trillion signals monthly from 245 million U.S. consumers, helping brands deliver personalized experiences at scale.

Zeta's Q2 2025 results showcased the power of this approach. Revenue surged 35% year over year to $308 million, while adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) jumped 52% to $59 million. This isn't just growth. It's profitable growth. Platform direct revenue now represents 74% of total revenue, up from 67% a year ago, driving gross margins higher.

The market opportunity ahead is massive. Digital marketing spend is expected to reach $1.3 trillion globally by 2027, and Zeta is positioned to capture a growing share. Unlike competitors that focus on single channels, Zeta's platform integrates 245 million consumer profiles with proprietary identity resolution technology, creating a moat that even tech giants struggle to replicate.

Zeta's Agentforce AI can create, test, and optimize marketing campaigns autonomously, reducing what once took weeks to hours. The platform integrates with Microsoft Azure and Salesforce ecosystems and serves multiple Fortune 500 clients -- validation that even tech giants see value in partnering rather than competing. With the stock trading at $20 against average analyst targets of $26, with some reaching $30, the upside potential reflects Zeta's transition from growth to profitable scale.

Flying taxis aren't science fiction

Perhaps no company better embodies innovation than Vertical Aerospace (NYSE: EVTL). The British company's VX4 electric vertical takeoff and landing (eVTOL) aircraft could transform urban transportation. Imagine traveling from Manhattan to JFK Airport in eight minutes instead of an hour.

In July 2025, the VX4 completed the world's first airport-to-airport eVTOL flight. The aircraft can carry four passengers plus a pilot, fly at 200 mph, and operate fully electric with zero operational emissions. More importantly, it promises operating costs 40% lower than helicopters while being 100 times quieter.

The business case is compelling. Vertical holds a $6 billion conditional preorder book from partners including American Airlines, Virgin Atlantic, and Avolon. With certification targeted for 2028 and commercial operations beginning soon after, management projects reaching profitability by 2030.

Yes, these timelines are aggressive -- this is an entirely new category of aircraft requiring unprecedented regulatory frameworks, and investors should prepare for potential delays. But at $5.45 per share versus analyst targets of $11, early investors are paying start-up prices for what could transform urban transportation.

The innovation premium

These three companies share a common thread: They're solving massive problems with innovative solutions; aTyr could transform autoimmune treatment; Zeta is making AI-powered marketing accessible; Vertical promises to unclog urban transportation.

Each faces significant risks: Clinical trials can fail; regulatory timelines can stretch; and well-funded competitors lurk. But for investors with long-term horizons who can stomach volatility, the potential rewards could justify the risks.

Should you invest $1,000 in Zeta Global right now?

Before you buy stock in Zeta Global, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Zeta Global wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $635,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,099,758!*

Now, it’s worth noting Stock Advisor’s total average return is 1,046% — a market-crushing outperformance compared to 181% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of August 4, 2025

George Budwell has positions in Microsoft and aTyr Pharma. The Motley Fool has positions in and recommends Microsoft and Salesforce. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.